Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome

F. D'Ovidio, H. Kaneda, C. Chaparro, M. Mura, D. Lederer, S. Di Angelo, H. Takahashi, C. Gutierrez, M. Hutcheon, L. G. Singer, T. K. Waddell, Joanna Floros, M. Liu, S. Keshavjee

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Primary graft failure and chronic lung allograft dysfunction (CLAD) limit lung transplant long-term outcomes. Various lung diseases have been correlated with surfactant protein (SP) expression and polymorphisms. We sought to investigate the role of SP expression in lung allografts prior to implantation, in relation to posttransplant outcomes. The expression of SP-(A, B, C, D) mRNA was assayed in 42 allografts. Posttransplant assessments include pulmonary function tests, bronchoscopy, broncho-alveolar lavage fluid (BALF) and biopsies to determine allograft rejection. BALF was assayed for SP-A, SP-D in addition to cytokines IL-8, IL-12 and IL-2. The diagnosis of CLAD was evaluated 6 months after transplantation. Lung allografts with low SP-A mRNA expression prior to implantation reduced survival (Log-rank p < 0.0001). No association was noted for the other SPs. Allografts with low SP-A mRNA had greater IL-2 (p = 0.03) and IL-12 (p < 0.0001) in the BALF and a greater incidence of rejection episodes (p = 0.003). Levels of SP-A mRNA expression were associated with the SP-A2 polymorphisms (p = 0.015). Specifically, genotype 1A1A0 was associated with lower SP-A mRNA expression (p < 0.05). Lung allografts with low levels of SP-A mRNA expression are associated with reduced survival. Lung allograft SP-A mRNA expression appears to be associated with SP-A gene polymorphisms. This study shows that low expression, prior to implantation, of donor lung innate immunity molecule surfactant protein SP-A, with varying levels according to the gene polymorphisms, is associated with the recipient's post-lung transplant clinical outcome.

Original languageEnglish (US)
Pages (from-to)2722-2729
Number of pages8
JournalAmerican Journal of Transplantation
Volume13
Issue number10
DOIs
StatePublished - Jan 1 2013

Fingerprint

Pulmonary Surfactant-Associated Proteins
Pulmonary Surfactant-Associated Protein A
Allografts
Transplants
Lung
Messenger RNA
Surface-Active Agents
Bronchoalveolar Lavage Fluid
Interleukin-12
Interleukin-2
Proteins
Pulmonary Surfactant-Associated Protein D
Respiratory Function Tests
Bronchoscopy
Interleukin-8
varespladib methyl
Innate Immunity
Lung Diseases
Genes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

D'Ovidio, F., Kaneda, H., Chaparro, C., Mura, M., Lederer, D., Di Angelo, S., ... Keshavjee, S. (2013). Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome. American Journal of Transplantation, 13(10), 2722-2729. https://doi.org/10.1111/ajt.12407
D'Ovidio, F. ; Kaneda, H. ; Chaparro, C. ; Mura, M. ; Lederer, D. ; Di Angelo, S. ; Takahashi, H. ; Gutierrez, C. ; Hutcheon, M. ; Singer, L. G. ; Waddell, T. K. ; Floros, Joanna ; Liu, M. ; Keshavjee, S. / Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome. In: American Journal of Transplantation. 2013 ; Vol. 13, No. 10. pp. 2722-2729.
@article{156c0d831c6643c9bf2d037ae0156bc7,
title = "Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome",
abstract = "Primary graft failure and chronic lung allograft dysfunction (CLAD) limit lung transplant long-term outcomes. Various lung diseases have been correlated with surfactant protein (SP) expression and polymorphisms. We sought to investigate the role of SP expression in lung allografts prior to implantation, in relation to posttransplant outcomes. The expression of SP-(A, B, C, D) mRNA was assayed in 42 allografts. Posttransplant assessments include pulmonary function tests, bronchoscopy, broncho-alveolar lavage fluid (BALF) and biopsies to determine allograft rejection. BALF was assayed for SP-A, SP-D in addition to cytokines IL-8, IL-12 and IL-2. The diagnosis of CLAD was evaluated 6 months after transplantation. Lung allografts with low SP-A mRNA expression prior to implantation reduced survival (Log-rank p < 0.0001). No association was noted for the other SPs. Allografts with low SP-A mRNA had greater IL-2 (p = 0.03) and IL-12 (p < 0.0001) in the BALF and a greater incidence of rejection episodes (p = 0.003). Levels of SP-A mRNA expression were associated with the SP-A2 polymorphisms (p = 0.015). Specifically, genotype 1A1A0 was associated with lower SP-A mRNA expression (p < 0.05). Lung allografts with low levels of SP-A mRNA expression are associated with reduced survival. Lung allograft SP-A mRNA expression appears to be associated with SP-A gene polymorphisms. This study shows that low expression, prior to implantation, of donor lung innate immunity molecule surfactant protein SP-A, with varying levels according to the gene polymorphisms, is associated with the recipient's post-lung transplant clinical outcome.",
author = "F. D'Ovidio and H. Kaneda and C. Chaparro and M. Mura and D. Lederer and {Di Angelo}, S. and H. Takahashi and C. Gutierrez and M. Hutcheon and Singer, {L. G.} and Waddell, {T. K.} and Joanna Floros and M. Liu and S. Keshavjee",
year = "2013",
month = "1",
day = "1",
doi = "10.1111/ajt.12407",
language = "English (US)",
volume = "13",
pages = "2722--2729",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "10",

}

D'Ovidio, F, Kaneda, H, Chaparro, C, Mura, M, Lederer, D, Di Angelo, S, Takahashi, H, Gutierrez, C, Hutcheon, M, Singer, LG, Waddell, TK, Floros, J, Liu, M & Keshavjee, S 2013, 'Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome', American Journal of Transplantation, vol. 13, no. 10, pp. 2722-2729. https://doi.org/10.1111/ajt.12407

Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome. / D'Ovidio, F.; Kaneda, H.; Chaparro, C.; Mura, M.; Lederer, D.; Di Angelo, S.; Takahashi, H.; Gutierrez, C.; Hutcheon, M.; Singer, L. G.; Waddell, T. K.; Floros, Joanna; Liu, M.; Keshavjee, S.

In: American Journal of Transplantation, Vol. 13, No. 10, 01.01.2013, p. 2722-2729.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pilot study exploring lung allograft surfactant protein A (SP-A) expression in association with lung transplant outcome

AU - D'Ovidio, F.

AU - Kaneda, H.

AU - Chaparro, C.

AU - Mura, M.

AU - Lederer, D.

AU - Di Angelo, S.

AU - Takahashi, H.

AU - Gutierrez, C.

AU - Hutcheon, M.

AU - Singer, L. G.

AU - Waddell, T. K.

AU - Floros, Joanna

AU - Liu, M.

AU - Keshavjee, S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Primary graft failure and chronic lung allograft dysfunction (CLAD) limit lung transplant long-term outcomes. Various lung diseases have been correlated with surfactant protein (SP) expression and polymorphisms. We sought to investigate the role of SP expression in lung allografts prior to implantation, in relation to posttransplant outcomes. The expression of SP-(A, B, C, D) mRNA was assayed in 42 allografts. Posttransplant assessments include pulmonary function tests, bronchoscopy, broncho-alveolar lavage fluid (BALF) and biopsies to determine allograft rejection. BALF was assayed for SP-A, SP-D in addition to cytokines IL-8, IL-12 and IL-2. The diagnosis of CLAD was evaluated 6 months after transplantation. Lung allografts with low SP-A mRNA expression prior to implantation reduced survival (Log-rank p < 0.0001). No association was noted for the other SPs. Allografts with low SP-A mRNA had greater IL-2 (p = 0.03) and IL-12 (p < 0.0001) in the BALF and a greater incidence of rejection episodes (p = 0.003). Levels of SP-A mRNA expression were associated with the SP-A2 polymorphisms (p = 0.015). Specifically, genotype 1A1A0 was associated with lower SP-A mRNA expression (p < 0.05). Lung allografts with low levels of SP-A mRNA expression are associated with reduced survival. Lung allograft SP-A mRNA expression appears to be associated with SP-A gene polymorphisms. This study shows that low expression, prior to implantation, of donor lung innate immunity molecule surfactant protein SP-A, with varying levels according to the gene polymorphisms, is associated with the recipient's post-lung transplant clinical outcome.

AB - Primary graft failure and chronic lung allograft dysfunction (CLAD) limit lung transplant long-term outcomes. Various lung diseases have been correlated with surfactant protein (SP) expression and polymorphisms. We sought to investigate the role of SP expression in lung allografts prior to implantation, in relation to posttransplant outcomes. The expression of SP-(A, B, C, D) mRNA was assayed in 42 allografts. Posttransplant assessments include pulmonary function tests, bronchoscopy, broncho-alveolar lavage fluid (BALF) and biopsies to determine allograft rejection. BALF was assayed for SP-A, SP-D in addition to cytokines IL-8, IL-12 and IL-2. The diagnosis of CLAD was evaluated 6 months after transplantation. Lung allografts with low SP-A mRNA expression prior to implantation reduced survival (Log-rank p < 0.0001). No association was noted for the other SPs. Allografts with low SP-A mRNA had greater IL-2 (p = 0.03) and IL-12 (p < 0.0001) in the BALF and a greater incidence of rejection episodes (p = 0.003). Levels of SP-A mRNA expression were associated with the SP-A2 polymorphisms (p = 0.015). Specifically, genotype 1A1A0 was associated with lower SP-A mRNA expression (p < 0.05). Lung allografts with low levels of SP-A mRNA expression are associated with reduced survival. Lung allograft SP-A mRNA expression appears to be associated with SP-A gene polymorphisms. This study shows that low expression, prior to implantation, of donor lung innate immunity molecule surfactant protein SP-A, with varying levels according to the gene polymorphisms, is associated with the recipient's post-lung transplant clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=84884900369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884900369&partnerID=8YFLogxK

U2 - 10.1111/ajt.12407

DO - 10.1111/ajt.12407

M3 - Article

VL - 13

SP - 2722

EP - 2729

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 10

ER -